ArticleCureus2025
When Being Overweight Masks the Diagnosis: Identifying Familial Hypercholesterolemia in Pediatric Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial hypercholesterolemia (FH) is a genetic disorder leading to elevated low-density lipoprotein cholesterol (LDL-C) from early life, significantly increasing the risk of premature atherosclerotic cardiovascular disease. Despite its prevalence, FH remains underdiagnosed, particularly in pediatric populations where obesity may obscure clinical suspicion. Here, we present two Georgian siblings diagnosed with heterozygous familial hypercholesterolemia (HeFH). The index patient, a nine-year-old boy, presented with overweight and elevated LDL-C that persisted despite weight loss. Evaluation of his brother, with a normal body mass index, and family members revealed similar lipid profiles, prompting the diagnosis of FH. Both siblings were started on atorvastatin 10 mg daily, resulting in significant LDL-C reduction without adverse effects. This case highlights the importance of distinguishing primary from secondary causes of dyslipidemia in children. The cumulative cholesterol burden from early life necessitates timely diagnosis and intervention. Obesity may mask FH, contributing to delays in recognition and management. Early clinical suspicion, comprehensive family screening, and timely initiation of statin therapy are essential for effective management of pediatric HeFH and the prevention of long-term cardiovascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.